Related Experiment Video

Updated: Oct 9, 2025

Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
06:51

Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research

Published on: October 20, 2023

1.3K

Amyloid Cardiopathy and Aortic Stenosis

Leonida Gherasim1

  • 1"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Maedica
|December 20, 2021
PubMed

Insights

Cardiac amyloidosis (CA) is often seen with aortic stenosis (AS). Diagnosing CA involves assessing AS severity and specific tests, with new treatments emerging for ATTR amyloidosis.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Amyloidosis Research

Background:

  • Cardiac amyloidosis (CA) is increasingly diagnosed, particularly in older patients with heart failure with preserved ejection fraction.
  • A significant subset of patients with severe aortic stenosis (AS) also have transthyretin amyloid cardiomyopathy (CA-ATTR), impacting diagnosis, prognosis, and treatment.
  • High suspicion for CA is indicated by biventricular hypertrophy (≥15 mm) and specific clinical 'red flags'.

Discussion:

  • Diagnosing CA, with or without AS, is complex and requires careful assessment of AS severity.
  • Diagnostic accuracy is enhanced by specific tests like bone scintigraphy and the absence of monoclonal light chains.
  • Genetic testing is crucial for differentiating senile and hereditary transthyretin (ATTR) types of CA.

Key Insights:

  • Pharmacological management of CA with heart failure requires cautious use of certain medications like beta-blockers and ACE inhibitors, with diuretics used to maintain euvolemia.
  • Aortic valve replacement (AVR), either transcatheter (TAVR) or surgical (SAVR), is recommended for severe AS associated with CA, with TAVR showing favorable comparative results.
  • Emerging pharmacological agents targeting CA-ATTR hold promise for significantly altering the management landscape of ATTR amyloidosis.

Outlook:

  • Further comparative studies on TAVR versus SAVR are needed to refine treatment strategies for AS in CA patients.
  • Continued research into novel pharmacological agents will likely transform the treatment of ATTR amyloidosis.
  • Improved diagnostic pathways and targeted therapies are expected to enhance outcomes for patients with cardiac amyloidosis.

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.2K

Related Concept Videos

Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
75
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
80
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
115
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
80
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
86
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
60